In contrast, high‐risk MDS is typically associated with an anti‐apoptotic phenotype, with upregulation of the anti‐apoptotic protein Bcl‐2 and a reduction in apoptotic cell markers like Apo2.7 in CD34+ cells [15, 26]. Here, BCL2 is linked to myelodysplastic syndrome.